Wednesday, June 10, 2015 2:09:20 PM
What roadblocks are you referring to in 2015?
As others have said, in the bio tech area, you don't expect to file an IND or discover a new drug and go to clinical trials in 6 months or a year. All these things take time and many trials do not even succeed.
While I agree the history of development in the past has been less than desired, 2015 has been a big improvement with full time research scientists, new lab space, actual contracting with reputed company CRL for final safety testing etc. While many company's products have failed the trials, so far we haven't encountered any scientific setback that I'm aware of, only management/communication/business dealing types of setbacks.
If HemaX doesn't pass safety testing at CRL, then we will have a big scientific setback and company roadblock, but on the other hand, if it passes, we most likely have an approved IND within 30 days of the test results being filed.
As others have said, in the bio tech area, you don't expect to file an IND or discover a new drug and go to clinical trials in 6 months or a year. All these things take time and many trials do not even succeed.
While I agree the history of development in the past has been less than desired, 2015 has been a big improvement with full time research scientists, new lab space, actual contracting with reputed company CRL for final safety testing etc. While many company's products have failed the trials, so far we haven't encountered any scientific setback that I'm aware of, only management/communication/business dealing types of setbacks.
If HemaX doesn't pass safety testing at CRL, then we will have a big scientific setback and company roadblock, but on the other hand, if it passes, we most likely have an approved IND within 30 days of the test results being filed.
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
